RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .
Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.
OBJECTIVE Irbesartan was renoprotective independently of its blood pressure-lowering effect in the Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria ( IRMA2 ) study . However , blood pressure was evaluated by trough office blood pressure ( OBP ) , which may underestimate reductions in 24-h ambulatory blood pressure ( ABP ) . In the present study , we evaluated 24-h blood pressure patterns in a sub population of the IRMA2 trial . RESEARCH DESIGN AND METHODS Type 2 diabetic patients ( n = 43 ) with persistent microalbuminuria ( as determined by repeated overnight measurements of urinary albumin excretion [ UAE ] ) and hypertension who were included in the IRMA2 study at the Steno Diabetes Center were subjected to 24-h ABP ( Takeda , TM2420 ) measurements before and 2 years after r and omization to placebo ( n = 15 ) , irbesartan 150 mg daily ( Irb150 ; n = 13 ) , or irbesartan 300 mg daily ( Irb300 ; n = 15 ) . RESULTS At baseline , the placebo , Irb150 , and Irb300 groups were comparable : OBP : 157 + /- 15/89 + /- 7 , 156 + /-15/91 + /- 11 , and 159 + /- 16/90 + /- 9 mmHg ( NS ) ; 24-h ABP : 148 + /- 13/83 + /- 11 , 148 + /- 16/82 + /- 7 and 147 + /- 16/81 + /- 10 mmHg ( NS ) ; and UAE ( geometric mean with 95 % CI ) : 43 ( 32 - 57 ) , 46 ( 30 - 70 ) , and 59 ( 42 - 85 ) micro g/min ( NS ) , respectively . We found that 2 years after r and omization , OBP was significantly reduced in all three groups ( by 11/7 , 13/8 , and 13/8 mmHg in the placebo , Irb150 , and Irb300 groups , respectively ) , but that there were no significant differences among groups . Reductions in 24-h ABP were similar in the three groups ( 11/10 , 5/7 , and 7/8 mmHg , respectively ; NS ) , as were reductions in day ABP ( 11/9 , 7/7 , and 8/9 mmHg , respectively ; NS ) and night ABP ( 4/11 , 7/7 , and 3/3 mmHg , respectively ; NS ) . The reduction in UAE at the end of the study was 0 % ( -86 to 42 ) , 38 % ( -14 to 66 ) , and 73 % ( 59 to 82 ) , respectively ( overall , P < 0.01 ) . CONCLUSION Irbesartan is renoprotective independently of its beneficial effect in lowering 24-h blood pressure in patients with type 2 diabetes and persistent microalbuminuria
RESULTS The global antihypertensive activity of ARB differs from that observed with amlodipine in the sense that the magnitude of the reduction in the BP values does not essentially depend on the initial BP values nor on the dose used .
When only ARB were considered , the drug used was a determinant for systolic BP reduction , whereas for diastolic BP the influence was on the BP reduction and the duration of the antihypertensive activity .
The dose used had a particular influence on the duration of the antihypertensive activity for both systolic and diastolic BP .
CONCLUSION Among the ARB , the influence is on duration more than on the magnitude of BP reduction .
Dose , therefore , is an important factor in the duration of antihypertensive activity
OBJECTIVE To perform a systematic review of the antihypertensive activity of the angiotensin II AT1 receptor antagonists ( ARB ) .